66 related articles for article (PubMed ID: 22296587)
1. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
Wilbur DS; Chyan MK; Nakamae H; Chen Y; Hamlin DK; Santos EB; Kornblit BT; Sandmaier BM
Bioconjug Chem; 2012 Mar; 23(3):409-20. PubMed ID: 22296587
[TBL] [Abstract][Full Text] [Related]
2. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
Aneheim E; Halleröd J; Albertsson P; Jensen H; Holgersson S; Lindegren S
Cancer Biother Radiopharm; 2015 Feb; 30(1):41-5. PubMed ID: 25588020
[TBL] [Abstract][Full Text] [Related]
3. Novel partial reduction of the humanized anti-cocaine mAb h2E2 for selective cysteine labeling.
Kirley TL; Norman AB
Biochem Biophys Res Commun; 2024 Jan; 692():149362. PubMed ID: 38071891
[TBL] [Abstract][Full Text] [Related]
4. Silicon-Containing Thiol-Specific Bioconjugating Reagent.
Zhang Z; Li L; Xu H; Lee CK; Jia Z; Loh TP
J Am Chem Soc; 2024 Jan; 146(3):1776-1782. PubMed ID: 38198597
[TBL] [Abstract][Full Text] [Related]
5. Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.
Coll RP; Bright SJ; Martinus DKJ; Georgiou DK; Sawakuchi GO; Manning HC
Mol Imaging Biol; 2023 Dec; 25(6):991-1019. PubMed ID: 37845582
[TBL] [Abstract][Full Text] [Related]
6. Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy.
Iizuka Y; Manabe Y; Ooe K; Toyoshima A; Yin X; Haba H; Kabayama K; Fukase K
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298546
[TBL] [Abstract][Full Text] [Related]
7. [
Laszlo GS; Sandmaier BM; Kehret AR; Orozco JJ; Hamlin DK; Dexter SL; Lim SYT; Cole FM; Huo J; Wilbur DS; Walter RB
Leuk Lymphoma; 2023; 64(7):1335-1339. PubMed ID: 37170642
[No Abstract] [Full Text] [Related]
8. Development of [
Laszlo GS; Orozco JJ; Kehret AR; Lunn MC; Huo J; Hamlin DK; Scott Wilbur D; Dexter SL; Comstock ML; O'Steen S; Sandmaier BM; Green DJ; Walter RB
Leukemia; 2022 Jun; 36(6):1485-1491. PubMed ID: 35474099
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates.
Kang MS; Kong TWS; Khoo JYX; Loh TP
Chem Sci; 2021 Oct; 12(41):13613-13647. PubMed ID: 34760149
[TBL] [Abstract][Full Text] [Related]
10. Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications.
Trujillo-Nolasco M; Morales-Avila E; Cruz-Nova P; Katti KV; Ocampo-García B
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452084
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".
Eychenne R; Chérel M; Haddad F; Guérard F; Gestin JF
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34207408
[TBL] [Abstract][Full Text] [Related]
12. Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".
Nakaya A; Qiu H; Santos EB; Hamlin DK; Wilbur DS; Storb R; Sandmaier BM
Transplant Cell Ther; 2021 Jun; 27(6):476.e1-476.e7. PubMed ID: 33775618
[TBL] [Abstract][Full Text] [Related]
13. Fused 1,2-Diboraoxazoles Based on
Voinova VV; Selivanov NA; Plyushchenko IV; Vokuev MF; Bykov AY; Klyukin IN; Novikov AS; Zhdanov AP; Grigoriev MS; Rodin IA; Zhizhin KY; Kuznetsov NT
Molecules; 2021 Jan; 26(1):. PubMed ID: 33466558
[TBL] [Abstract][Full Text] [Related]
14. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.
Nelson BJB; Andersson JD; Wuest F
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396374
[TBL] [Abstract][Full Text] [Related]
15. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.
Li Y; Chyan MK; Hamlin DK; Nguyen H; Vessella R; Wilbur DS
Nucl Med Biol; 2021 Jan; 92():217-227. PubMed ID: 32409263
[TBL] [Abstract][Full Text] [Related]
17. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S; Albertsson P; Bäck T; Jensen H; Palm S; Aneheim E
Cancer Biother Radiopharm; 2020 Aug; 35(6):425-436. PubMed ID: 32077749
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio-Crosslinking.
Denk C; Wilkovitsch M; Aneheim E; Herth MM; Jensen H; Lindegren S; Mikula H
Chempluschem; 2019 Jul; 84(7):775-778. PubMed ID: 31681526
[TBL] [Abstract][Full Text] [Related]
19. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
O'Steen S; Comstock ML; Orozco JJ; Hamlin DK; Wilbur DS; Jones JC; Kenoyer A; Nartea ME; Lin Y; Miller BW; Gooley TA; Tuazon SA; Till BG; Gopal AK; Sandmaier BM; Press OW; Green DJ
Blood; 2019 Oct; 134(15):1247-1256. PubMed ID: 31395601
[TBL] [Abstract][Full Text] [Related]
20.
Fujiki K; Kanayama Y; Yano S; Sato N; Yokokita T; Ahmadi P; Watanabe Y; Haba H; Tanaka K
Chem Sci; 2019 Feb; 10(7):1936-1944. PubMed ID: 30881623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
